These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 31088908)

  • 1. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
    Rapisarda A; Melillo G
    Oncogene; 2007 Oct; 26(48):6875-84. PubMed ID: 17496931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
    Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
    Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
    Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
    Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
    Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
    Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
    Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells.
    Mai L; Luo M; Wu JJ; Yang JH; Hong LY
    Neoplasma; 2019 Sep; 66(5):776-784. PubMed ID: 31169018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
    Ao Q; Su W; Guo S; Cai L; Huang L
    Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
    Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
    Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1α.
    Li DW; Dong P; Wang F; Chen XW; Xu CZ; Zhou L
    Asian Pac J Cancer Prev; 2013; 14(8):4853-8. PubMed ID: 24083758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.